Table 1 Characteristics of MSM study participants at enrolment into CANOC (n = 2858)
Characteristic | Total (%)a |
|---|---|
Province | |
 British Columbia | 854 (30) |
 Ontario | 1045 (37) |
 Quebec | 959 (34) |
Age (years) | 40 (34–46) |
Ethnicity | |
 Caucasian | 1320 (46) |
 Black | 51 (2) |
 Aboriginal | 70 (2) |
 Other | 371 (13) |
 Unknown | 1046 (37) |
History of IDU | |
 No | 2555 (89) |
 Yes | 247 (9) |
 Unknown | 56 (2) |
Hepatitis C status | |
 No | 2413 (84) |
 Yes | 331 (12) |
 Unknown | 114 (4) |
Era of cART initiation | |
 2000–2003 | 729 (26) |
 2004–2007 | 931 (33) |
 2008–2012 | 1198 (42) |
Number of viral load tests per year | |
 Less than 3 | 583 (20) |
 3–4 | 1590 (56) |
 5–6 | 360 (13) |
 More than 6 | 325 (11) |
Initial 3rd ARV class | |
 NNRTI | 1277 (45) |
 Unboosted PI | 128 (4) |
 Boosted PI | 1239 (43) |
 Other | 214 (7) |
Initial 3rd ARV | |
 Nevirapine | 252 (9) |
 Efavirenz | 1033 (36) |
 Lopinavir | 424 (15) |
 Atazanavir | 578 (20) |
 Other | 571 (20) |
NRTI combination | |
 Tenofovir/emtricitabine | 1217 (43) |
 Zidovudine/lamivudine | 594 (21) |
 Tenofovir/lamivudine | 207 (7) |
 Abacavir/lamivudine | 468 (16) |
 Stavudine/lamivudine | 212 (7) |
 Other | 160 (6) |
AIDS-defining illness | |
 No | 2284 (80) |
 Yes | 459 (16) |
 Unknown | 115 (4) |
Viral load (log10 copies/mL) | 4.96 (4.51–5.00) |
CD4 count (cells/uL) | 230 (130–321) |